Investments within BioXData

Drugs are only as good as what they target, and the field has been using the same targets randomly discovered through academic work. Cartography is the first company to systematically profile healthy and diseased tissue cell-by-cell to discover robust targets that lead to better, safer drugs.

Clear Labs's automation, lower cost, and productization makes pathogen sequencing far more accessible, tranforming time to intervention with data relevant to many diseases and medical conditions.

Deepsight will significantly improve ultrasound performance making this safe, non-invasive technology far more usable.

Proteomics lags genomics in speed and accuracy of sequencing. Glyphic's approach will solve this at scale unlocking a massively valuable bio dataset.

Today it's impossible to get real-time metabolic insights on biology, an incredibly important dataset for the life sciences. Matterworks' ML approach enables real-time insights into cellular biology.

Growing cells is the first step in creating drugs that work, yet today it's an artisinal, error-prone process run by over-qualified scientist. Mytos fully automates manufacture of any human cell types.

OverT combines leading cell engineering technology with big data to create better treatments for solid tumors.

Despite genomics advancements there is still a tremendous unmet need for higher sensitivity with high specificity in early cancer detection. PrognomIQ generates multiomic data at scale in their next-gen approach to early cancer detection.

Learn more about Seer and why we invested in their vision. At Wing we’re committed to helping founders like Omid Farokhzad do their best work.

70% of drug targets are too complex for small molecules and beyond the reach of biologics. Unnatural Product's ML platform engineers macrocycles to drug today's undruggable.

Drug discovery is only as powerful as the data that fuels it, and today that data is generated out of context from how disease occurs in living organisms while also failing to account for the diverse mosaic of genetic backgrounds across patients. Vevo is the first platform to make in vivo data generation scalable bringing this important context earlier in drug development to create better drugs.